In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers

Journal of Proteomics

Volumn 103, Issue , 2014, Pages 121-136

  Karagiannis, George S ^a,b   Pavlou, Maria P ^a,b   Saraon, Punit ^a,b   Musrap, Natasha ^a,b   Xie, Annie ^a   Batruch, Ihor ^b   Prassas, Ioannis ^b   Dimitromanolakis, Apostolos ^b   Petraki, Constantina ^c   Diamandis, Eleftherios P ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c METROPOLITAN HOSPITAL   (Greece)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Colorectal cancer; Enrichment map analysis; Exoproteome; Kallikrein related peptidase; Olfactomedin 4; Proteomics

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; OLFM4 PROTEIN, HUMAN; PROTEOME; TUMOR MARKER; TUMOR PROTEIN;

BLOOD; COLON TUMOR; COLORECTAL TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PROCEDURES; PROTEOMICS; SECRETION (PROCESS); TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

CELL LINE, TUMOR; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84898795759     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.03.018     Document Type: Article

References (133)

1. Haggar F.A., Boushey R.P. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009, 22:191-197.
2. Jemal A., Bray F., Center M.M., Ferlay J., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Zavoral M., Suchanek S., Zavada F., Dusek L., et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009, 15:5907-5915.
4. Erdman S.E., Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol 2009, 38:76-87.
5. Fox J.G., Ge Z., Whary M.T., Erdman S.E., Horwitz B.H. Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer. Mucosal Immunol 2010, 4:22-30.
6. Galiatsatos P., Foulkes W.D. Familial adenomatous polyposis. Am J Gastroenterol 2006, 101:385-398.
7. Half E., Bercovich D., Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009, 4:22.
8. Lynch H.T., Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 1996, 78:1149-1167.
9. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
10. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009, 361:2449-2460.
11. Ilyas M., Straub J., Tomlinson I.P., Bodmer W.F. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999, 35:335-351.
12. Al-Sohaily S., Biankin A., Leong R., Kohonen-Corish M., Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol 2012, 27:1423-1431.
13. Smith G., Carey F.A., Beattie J., Wilkie M.J., et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002, 99:9433-9438.
14. Gryfe R., Swallow C., Bapat B., Redston M., et al. Molecular biology of colorectal cancer. Curr Probl Cancer 1997, 21:233-300.
15. Bright-Thomas R.M., Hargest R. APC, beta-Catenin and hTCF-4; an unholy trinity in the genesis of colorectal cancer. Eur J Surg Oncol 2003, 29:107-117.
16. Hedrick L., Cho K.R., Fearon E.R., Wu T.C., et al. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994, 8:1174-1183.
17. Russo A., Bazan V., Iacopetta B., Kerr D., et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005, 23:7518-7528.
18. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010, 138:2073-2087. [e2073].
19. Stone J.G., Tomlinson I.P., Houlston R.S. Optimising methods for determining RER status in colorectal cancers. Cancer Lett 2000, 149:15-20.
20. Karagiannis G.S., Pavlou M.P., Diamandis E.P. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol 2010, 4:496-510.
21. Kulasingam V., Pavlou M.P., Diamandis E.P. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010, 10:371-378.
22. Jain K.K. Innovations, challenges and future prospects of oncoproteomics. Mol Oncol 2008, 2:153-160.
23. Tjalsma H., Bolhuis A., Jongbloed J.D., Bron S., van Dijl J.M. Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol Mol Biol Rev 2000, 64:515-547.
24. Antelmann H., Tjalsma H., Voigt B., Ohlmeier S., et al. A proteomic view on genome-based signal peptide predictions. Genome Res 2001, 11:1484-1502.
25. Desvaux M., Hebraud M., Talon R., Henderson I.R. Secretion and subcellular localizations of bacterial proteins: a semantic awareness issue. Trends Microbiol 2009, 17:139-145.
26. Desvaux M., Hebraud M., Talon R., Henderson I.R. Outer membrane translocation: numerical protein secretion nomenclature in question in mycobacteria. Trends Microbiol 2009, 17:338-340.
27. Armengaud J., Christie-Oleza J.A., Clair G., Malard V., Duport C. Exoproteomics: exploring the world around biological systems. Expert Rev Proteomics 2012, 9:561-575.
28. Chagnot C., Zorgani M.A., Astruc T., Desvaux M. Proteinaceous determinants of surface colonization in bacteria: bacterial adhesion and biofilm formation from a protein secretion perspective. Front Microbiol 2013, 4:303.
29. Tjalsma H. Feature-based reappraisal of the Bacillus subtilis exoproteome. Proteomics 2007, 7:73-81.
30. Pavlou M.P., Diamandis E.P. The cancer cell secretome: a good source for discovering biomarkers?. J Proteomics 1896-1906, 2010:73.
31. Kulasingam V., Diamandis E.P. Tissue culture-based breast cancer biomarker discovery platform. Int J Cancer 2008, 123:2007-2012.
32. Piersma S.R., Fiedler U., Span S., Lingnau A., et al. Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res 1913-1922, 2010:9.
33. Jimenez C.R., Piersma S., Pham T.V. High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery. Biomark Med 2007, 1:541-565.
34. Schaaij-Visser T.B., de Wit M., Lam S.W., Jimenez C.R. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta 1834, 2013:2242-2258.
35. Wu C.C., Chen H.C., Chen S.J., Liu H.P., et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008, 8:316-332.
36. Xue H., Lu B., Zhang J., Wu M., et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2009, 9:545-555.
37. Wu C.C., Hsu C.W., Chen C.D., Yu C.J., et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 2010, 9:1100-1117.
38. Barderas R., Mendes M., Torres S., Bartolome R.A., et al. In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol Cell Proteomics 2013, 12:1602-1620.
39. Zeng X., Yang P., Chen B., Jin X., et al. Quantitative secretome analysis reveals the interactions between epithelia and tumor cells by in vitro modulating colon cancer microenvironment. J Proteomics 2013, 89:51-70.
40. Emmink B.L., Verheem A., Van Houdt W.J., Steller E.J., et al. The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J Proteomics 2013, 91:84-96.
41. Van Houdt W.J., Emmink B.L., Pham T.V., Piersma S.R., et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics 2011, 10. [M111 011353].
42. Elias J.E., Gygi S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 2007, 4:207-214.
43. Choi H., Nesvizhskii A.I. False discovery rates and related statistical concepts in mass spectrometry-based proteomics. J Proteome Res 2008, 7:47-50.
44. Zhu W., Smith J.W., Huang C.M. Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol 2010, 840518.
45. Liu H., Sadygov R.G., Yates J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004, 76:4193-4201.
46. Bachi A., Bonaldi T. Quantitative proteomics as a new piece of the systems biology puzzle. J Proteomics 2008, 71:357-367.
47. Collier T.S., Randall S.M., Sarkar P., Rao B.M., et al. Comparison of stable-isotope labeling with amino acids in cell culture and spectral counting for relative quantification of protein expression. Rapid Commun Mass Spectrom 2011, 25:2524-2532.
48. Bendtsen J.D., Nielsen H., von Heijne G., Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 2004, 340:783-795.
49. Nielsen H., Engelbrecht J., Brunak S., von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng 1997, 10:1-6.
50. Bendtsen J.D., Jensen L.J., Blom N., Von Heijne G., Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 2004, 17:349-356.
51. Moller S., Croning M.D., Apweiler R. Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics 2001, 17:646-653.
52. Karagiannis G.S., Berk A., Dimitromanolakis A., Diamandis E.P. Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. Mol Oncol 2013, 7:826-839.
53. Maere S., Heymans K., Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005, 21:3448-3449.
54. Merico D., Isserlin R., Stueker O., Emili A., Bader G.D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 2010, 5:e13984.
55. Merico D., Isserlin R., Bader G.D. Visualizing gene-set enrichment results using the Cytoscape plug-in enrichment map. Methods Mol Biol 2011, 781:257-277.
56. Franceschini A., Szklarczyk D., Frankild S., Kuhn M., et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2012, 41:D808-D815.
57. Edgar R., Domrachev M., Lash A.E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210.
58. Parkinson H., Kapushesky M., Kolesnikov N., Rustici G., et al. ArrayExpress update-from an archive of functional genomics experiments to the atlas of gene expression. Nucleic Acids Res 2009, 37:D868-D872.
59. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
60. Lukk M., Kapushesky M., Nikkila J., Parkinson H., et al. A global map of human gene expression. Nat Biotechnol 2010, 28:322-324.
61. Luo L.Y., Soosaipillai A., Grass L., Diamandis E.P. Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients. Tumour Biol 2006, 27:227-234.
62. Shaw J.L., Diamandis E.P. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007, 53:1423-1432.
63. Petraki C., Dubinski W., Scorilas A., Saleh C., et al. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. Pathol Res Pract 2012, 208:104-108.
64. Petraki C.D., Karavana V.N., Luo L.Y., Diamandis E.P. Human kallikrein 10 expression in normal tissues by immunohistochemistry. J Histochem Cytochem 2002, 50:1247-1261.
65. Ruckert F., Hennig M., Petraki C.D., Wehrum D., et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer 2008, 99:1484-1492.
66. Petraki C., Youssef Y.M., Dubinski W., Lichner Z., et al. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol 2012, 33:1209-1214.
67. Makawita S., Smith C., Batruch I., Zheng Y., et al. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics 2011, 10. [M111 008599].
68. Sardana G., Jung K., Stephan C., Diamandis E.P. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008, 7:3329-3338.
69. Gunawardana C.G., Kuk C., Smith C.R., Batruch I., et al. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J Proteome Res 2009, 8:4705-4713.
70. Kulasingam V., Diamandis E.P. Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics 1997-2011, 2007:6.
71. Planque C., Kulasingam V., Smith C.R., Reckamp K., et al. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 2009, 8:2746-2758.
72. Saraon P., Musrap N., Cretu D., Karagiannis G.S., et al. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer. J Biol Chem 2012, 287:34019-34031.
73. Pavlou M.P., Dimitromanolakis A., Diamandis E.P. Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer. Proteomics 2013, 13:1083-1095.
74. Karagiannis G.S., Petraki C., Prassas I., Saraon P., et al. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget 2012, 3:267-285.
75. Borgono C.A., Diamandis E.P. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004, 4:876-890.
76. Borgono C.A., Michael I.P., Diamandis E.P. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004, 2:257-280.
77. Karagiannis G.S., Weile J., Bader G.D., Minta J. Integrative pathway dissection of molecular mechanisms of moxLDL-induced vascular smooth muscle phenotype transformation. BMC Cardiovasc Disord 2013, 13:4.
78. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
79. Karagiannis G.S., Poutahidis T., Erdman S.E., Kirsch R., et al. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res 2012, 10:1403-1418.
80. Doucet A., Butler G.S., Rodriguez D., Prudova A., Overall C.M. Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol Cell Proteomics 2008, 7:1925-1951.
81. Doucet A., Overall C.M. Protease proteomics: revealing protease in vivo functions using systems biology approaches. Mol Aspects Med 2008, 29:339-358.
82. Collins J.J., Black P.H. Specificity of the carcinoembryonic antigen (CEA). N Engl J Med 1971, 285:175-176.
83. Dallas M.R., Liu G., Chen W.C., Thomas S.N., et al. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J 2012, 26:2648-2656.
84. Thomas S.N., Zhu F., Schnaar R.L., Alves C.S., Konstantopoulos K. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem 2008, 283:15647-15655.
85. Kivela A.J., Parkkila S., Saarnio J., Karttunen T.J., et al. Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa. World J Gastroenterol 2005, 11:2616-2625.
86. Cleven A.H., Wouters B.G., Schutte B., Spiertz A.J., et al. Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis. Br J Cancer 2008, 99:727-733.
87. Sansone P., Piazzi G., Paterini P., Strillacci A., et al. Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J Cell Mol Med 2009, 13:3876-3887.
88. Smyth L.G., O'Hurley G., O'Grady A., Fitzpatrick J.M., et al. Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis 2009, 13:178-181.
89. Kobayashi D., Koshida S., Moriai R., Tsuji N., Watanabe N. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci 2007, 98:334-340.
90. Fong S.F., Dietzsch E., Fong K.S., Hollosi P., et al. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosomes Cancer 2007, 46:644-655.
91. Hollosi P., Yakushiji J.K., Fong K.S., Csiszar K., Fong S.F. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Int J Cancer 2009, 125:318-327.
92. Peinado H., Portillo F., Cano A. Switching on-off Snail: LOXL2 versus GSK3beta. Cell Cycle 2005, 4:1749-1752.
93. Mulvihill M.S., Kwon Y.W., Lee S., Fang L.T., et al. Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. PLoS One 2012, 7:e42264.
94. Sneddon J.B., Zhen H.H., Montgomery K., van de Rijn M., et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A 2006, 103:14842-14847.
95. Wistuba I.I., Behrens C., Milchgrub S., Syed S., et al. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res 1998, 4:2931-2938.
96. Wistuba I.I., Bryant D., Behrens C., Milchgrub S., et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res 1999, 5:991-1000.
97. Saraon P., Cretu D., Musrap N., Karagiannis G.S., et al. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteomics 2013, 12:1589-1601.
98. Tiger C.F., Krause F., Cedersund G., Palmer R., et al. A framework for mapping, visualisation and automatic model creation of signal-transduction networks. Mol Syst Biol 2012, 8:578.
99. Hanauer D.A., Rhodes D.R., Chinnaiyan A.M. Exploring clinical associations using '-omics' based enrichment analyses. PLoS One 2009, 4:e5203.
100. Bode C., Kovacs I.A., Szalay M.S., Palotai R., et al. Network analysis of protein dynamics. FEBS Lett 2007, 581:2776-2782.
101. Chu L.H., Chen B.S. Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets. BMC Syst Biol 2008, 2:56.
102. Csermely P., Korcsmaros T., Kovacs I.A., Szalay M.S., Soti C. Systems biology of molecular chaperone networks. Novartis Found Symp 2008, 291:45-54. [discussion 54-48, 137-140].
103. He X., Zhang J. Why do hubs tend to be essential in protein networks?. PLoS Genet 2006, 2:e88.
104. Levy S.F., Siegal M.L. Network hubs buffer environmental variation in Saccharomyces cerevisiae. PLoS Biol 2008, 6:e264.
105. Wang Y., Zhang X.S., Chen L. A network biology study on circadian rhythm by integrating various omics data. OMICS 2009, 13:313-324.
106. Beck S.E., Jung B.H., Fiorino A., Gomez J., et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 2006, 291:G135-G145.
107. Prassas I., Karagiannis G.S., Batruch I., Dimitromanolakis A., et al. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther 2011, 10:2083-2093.
108. Dooley S., Seib T., Engel M., Theisinger B., et al. Isolation and characterization of the human genomic locus coding for the putative metastasis control gene nm23-H1. Hum Genet 1994, 93:63-66.
109. Georges R.B., Adwan H., Hamdi H., Hielscher T., et al. The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis. Cancer Biol Ther 2011, 12:69-79.
110. Ruan W., Xu E., Xu F., Ma Y., et al. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther 2007, 6:354-359.
111. Ruan W.J., Lin J., Xu E.P., Xu F.Y., et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B 2006, 7:929-932.
112. Kirkpatrick J.P., Rabbani Z.N., Bentley R.C., Hardee M.E., et al. Elevated CAIX expression is associated with an increased risk of distant failure in early-stage cervical cancer. Biomark Insights 2008, 3:45-55.
113. Zimmermann D.R., Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 1989, 8:2975-2981.
114. Tisdale M.J. Zinc-alpha2-glycoprotein in cachexia and obesity. Curr Opin Support Palliat Care 2009, 3:288-293.
115. Hassan M.I., Waheed A., Yadav S., Singh T.P., Ahmad F. Zinc alpha 2-glycoprotein: a multidisciplinary protein. Mol Cancer Res 2008, 6:892-906.
116. Roll P., Vernes S.C., Bruneau N., Cillario J., et al. Molecular networks implicated in speech-related disorders: FOXP2 regulates the SRPX2/uPAR complex. Hum Mol Genet 2010, 19:4848-4860.
117. Tanaka K., Arao T., Maegawa M., Matsumoto K., et al. SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. Int J Cancer 2009, 124:1072-1080.
118. Miljkovic-Licina M., Hammel P., Garrido-Urbani S., Bradfield P.F., et al. Sushi repeat protein X-linked 2, a novel mediator of angiogenesis. FASEB J 2009, 23:4105-4116.
119. Gersemann M., Becker S., Nuding S., Antoni L., et al. Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD. J Crohns Colitis 2012, 6:425-434.
120. Liu W., Yan M., Liu Y., Wang R., et al. Olfactomedin 4 down-regulates innate immunity against Helicobacter pylori infection. Proc Natl Acad Sci U S A 2010, 107:11056-11061.
121. Liu W., Yan M., Sugui J.A., Li H., et al. Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease. J Clin Invest 2013, 123:3751-3755.
122. Grover P.K., Hardingham J.E., Cummins A.G. Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev 2010, 29:761-775.
123. Koshida S., Kobayashi D., Moriai R., Tsuji N., Watanabe N. Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci 2007, 98:315-320.
124. Sawada T., Yashiro M., Sentani K., Oue N., et al. New molecular staging with G-factors (VEGF-C and Reg IV) by supplementing TNM classification in colorectal cancers. Oncol Rep 2013, 30:2609-2616.
125. Yu L., Wang L., Chen S. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers. Neoplasma 2011, 58:9-13.
126. Besson D., Pavageau A.H., Valo I., Bourreau A., et al. A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol Cell Proteomics 2011, 10. [M111 009712].
127. Clemmensen S.N., Bohr C.T., Rorvig S., Glenthoj A., et al. Olfactomedin 4 defines a subset of human neutrophils. J Leukoc Biol 2012, 91:495-500.
128. Oue N., Sentani K., Noguchi T., Ohara S., et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer 2009, 125:2383-2392.
129. Luo Z., Zhang Q., Zhao Z., Li B., et al. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. J Cancer Res Clin Oncol 2011, 137:1713-1720.
130. Yu L., He M., Yang Z., Chen G., et al. Olfactomedin 4 is a marker for progression of cervical neoplasia. Int J Gynecol Cancer 2011, 21:367-372.
131. Navab R., Strumpf D., Bandarchi B., Zhu C.Q., et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 2011, 108:7160-7165.
132. Chen L., Li H., Liu W., Zhu J., et al. Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1. Carcinogenesis 2011, 32:986-994.
133. Park K.S., Kim K.K., Piao Z.H., Kim M.K., et al. Olfactomedin 4 suppresses tumor growth and metastasis of mouse melanoma cells through downregulation of integrin and MMP genes. Mol Cells 2012, 34:555-561.